Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Hls Therapeutics Inc (HLS.TO)

Hls Therapeutics Inc (HLS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 116,045
  • Shares Outstanding, K 31,793
  • Annual Sales, $ 63,074 K
  • Annual Income, $ -27,531 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.92
  • Price/Sales 1.45
  • Price/Cash Flow 9.65
  • Price/Book 1.03
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.69
  • Most Recent Earnings $-0.15 on 11/07/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend 0.050 on 04/27/23
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.13
  • Number of Estimates 3
  • High Estimate -0.11
  • Low Estimate -0.15
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.13 +13.10%
on 11/20/24
3.99 -11.28%
on 11/25/24
+0.17 (+5.04%)
since 11/13/24
3-Month
3.00 +18.00%
on 10/25/24
4.00 -11.50%
on 10/18/24
+0.28 (+8.59%)
since 09/13/24
52-Week
3.00 +18.00%
on 10/25/24
5.48 -35.40%
on 04/08/24
-0.15 (-4.07%)
since 12/13/23

Most Recent Stories

More News
HLS Therapeutics Announces Q3 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.54 (-3.01%)
Stocks in play: HLS Therapeutics Inc.

Will release its Q3 fiscal 2024 financial results on Thursday, November 7. The Company will hold a conference ...

HLS.TO : 3.54 (-3.01%)
HLS Therapeutics to Host Q3 Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 fiscal 2024 financial results on Thursday, November 7,...

HLS.TO : 3.54 (-3.01%)
Stocks in play: HLS Therapeutics Inc.

Announces that CEO Craig Millian, Chief Executive Officer, will present at H.C. Wainwright's 26th Annual ...

HLS.TO : 3.54 (-3.01%)
HLS Therapeutics to Present at H.C. Wainwright's 26th Annual Global Investment Conference

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.54 (-3.01%)
HLS Therapeutics Announces Q2 2024 Financial Results

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.54 (-3.01%)
Stocks in play: HLS Therapeutics Inc.

Announces that it has entered into a Product Listing Agreement with the province of Alberta, for the ...

HLS.TO : 3.54 (-3.01%)
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric...

HLS.TO : 3.54 (-3.01%)
Stocks in play: HLS Therapeutics Inc.

Will release its Q2 fiscal 2024 financial results on Thursday, August 8. The Company will hold a conference ...

HLS.TO : 3.54 (-3.01%)
HLS Therapeutics to Host Q2 Fiscal 2024 Financial Results Conference Call

/CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 fiscal 2024 financial results on Thursday, August 8,...

HLS.TO : 3.54 (-3.01%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Bearish.

See More Share

Business Summary

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product...

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 3.97
1st Resistance Point 3.81
Last Price 3.54
1st Support Level 3.47
2nd Support Level 3.29
3rd Support Level 3.13

See More

52-Week High 5.48
Fibonacci 61.8% 4.53
Fibonacci 50% 4.24
Fibonacci 38.2% 3.95
Last Price 3.54
52-Week Low 3.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar